Published in Medical Letter on the CDC and FDA, March 4th, 2007
Following a broad ranging review of Pollinex Quattro's preclinical, manufacturing and clinical data, and subject to minor clarifications, the FDA has accepted the company's plans to conduct a single pivotal phase 3 trial for registration.
With a clear understanding of the path to achieve the regulatory submission, the company is finalizing preparations for a randomized,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.